MeiraGTx Holdings plc appointed Alan M. Sebulsky to its board effective September 23, with his term running until the 2028 annual meeting and service on the Science and Technology Committee. The appointment matters to investors because Sebulsky’s background includes work with a biopharmaceutical portfolio exceeding $2 billion.

Key Highlights

  • Alan M. Sebulsky joined MeiraGTx’s board effective September 23.
  • His board term runs until the company’s 2028 annual meeting.
  • Sebulsky previously worked with a biopharmaceutical portfolio worth over $2 billion.

MeiraGTx Holdings plc (NASDAQ: MGTX) is a biotechnology company. Alan M. Sebulsky joined its board effective September 23, with his term extending until the 2028 annual meeting of shareholders. He will also serve on the Science and Technology Committee.

Board Term and Director Arrangements

The board approved the appointment on September 22 following a recommendation from its Nominating and Corporate Governance Committee. Senior management recommended Sebulsky as a potential board candidate. Sebulsky is eligible for compensation under MeiraGTx’s Non-Employee Director Compensation Program and is expected to enter the company’s standard indemnification agreement for directors and officers. The company said there are no related-party transactions between MeiraGTx and Sebulsky.

Biopharmaceutical Investment Experience

Sebulsky’s earlier work included Portfolio Management at BBT Capital Management Advisory LLC and investment roles at Lincoln Capital Management.